Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease

Recent studies have demonstrated the high analytical and diagnostic performance of plasma p-tau217 using well-defined cohorts. We aimed to assess the analytical, diagnostic, and prognostic utility of plasma p-tau217 as a routine biomarker in symptomatic patients attending our memory clinic. We also...

Full description

Bibliographic Details
Authors: Dakterzada, Farida, López Ortega, Ricard, Vilella-Figuerola, Alba, Montero-Castilla, Nathalia, Riba-Llena, Iolanda, Ruiz-Julián, Maria, Arias, Alfonso, Sarto, Jordi, Tahan, Nuria, Piñol Ripoll, Gerard
Format: article
Status:Published version
Publication Date:2025
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:dnet:recercat____::a36f2359956ad954bd0f0a335139c00d
Online Access:https://doi.org/10.3390/ijms26146771
https://hdl.handle.net/10459.1/470260
Access Level:Open access
Keyword:Alzheimer’s disease
Lumipulse
Biomarker
Mild cognitive impairment
p-tau181
p-tau217
Plasma
Progression
id ES_7ae3bb6fd71b935fa65ba8240260df9a
oai_identifier_str oai:dnet:recercat____::a36f2359956ad954bd0f0a335139c00d
network_acronym_str ES
network_name_str España
repository_id_str
spelling Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's DiseaseDakterzada, FaridaLópez Ortega, RicardVilella-Figuerola, AlbaMontero-Castilla, NathaliaRiba-Llena, IolandaRuiz-Julián, MariaArias, AlfonsoSarto, JordiTahan, NuriaPiñol Ripoll, GerardAlzheimer’s diseaseLumipulseBiomarkerMild cognitive impairmentp-tau181p-tau217PlasmaProgressionRecent studies have demonstrated the high analytical and diagnostic performance of plasma p-tau217 using well-defined cohorts. We aimed to assess the analytical, diagnostic, and prognostic utility of plasma p-tau217 as a routine biomarker in symptomatic patients attending our memory clinic. We also sought to identify optimal cutoff points that align with cerebrospinal fluid (CSF) amyloid beta (Aβ) status. A total of 276 cognitively impaired patients were included, with 81 mild cognitive impairment (MCI) patients followed for a mean of 56 (±15.8) months to evaluate progression to Alzheimer's disease (AD). CSF and blood biomarkers of AD were quantified using the Lumipulse G platform. Plasma p-tau217 levels showed strong correlations with CSF Aβ42/Aβ40 ( = -0.707), p-tau181/Aβ42 ( = 0.842), and p-tau181 (r 0.728). Plasma p-tau217 levels were significantly higher in the A + T + group than in A - T +/- ( < 0.001) and outperformed other plasma markers in detecting CSF Aβ pathology (AUC 0.924).Additionally, p-tau217 moderated cognitive changes over time as measured by the Mini-mental state examination (MMSE) (F(2, 70) = 13.995, < 0.001) and outperformed other plasma biomarkers in predicting progression from MCI to AD (AUC 0.876). Using a dual cutoff strategy, 72% of patients were classified with 94.9% concordance with CSF Aβ status. Plasma p-tau217 shows strong potential as a non-invasive, cost-effective diagnostic and prognostic tool in clinical settings.MDPI2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.3390/ijms26146771https://hdl.handle.net/10459.1/470260https://hdl.handle.net/10459.1/470260reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/ijms26146771International Journal of Molecular Sciences, 2025, vol. 26, núm. 14cc-by (c)The Authors, 2025Attribution 4.0 Internationalinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:dnet:recercat____::a36f2359956ad954bd0f0a335139c00d2026-05-29T05:05:01Z
dc.title.none.fl_str_mv Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
title Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
spellingShingle Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
Dakterzada, Farida
Alzheimer’s disease
Lumipulse
Biomarker
Mild cognitive impairment
p-tau181
p-tau217
Plasma
Progression
title_short Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
title_full Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
title_fullStr Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
title_full_unstemmed Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
title_sort Performance of Plasma Phosphorylated tau-217 in Patients on the Continuum of Alzheimer's Disease
dc.creator.none.fl_str_mv Dakterzada, Farida
López Ortega, Ricard
Vilella-Figuerola, Alba
Montero-Castilla, Nathalia
Riba-Llena, Iolanda
Ruiz-Julián, Maria
Arias, Alfonso
Sarto, Jordi
Tahan, Nuria
Piñol Ripoll, Gerard
author Dakterzada, Farida
author_facet Dakterzada, Farida
López Ortega, Ricard
Vilella-Figuerola, Alba
Montero-Castilla, Nathalia
Riba-Llena, Iolanda
Ruiz-Julián, Maria
Arias, Alfonso
Sarto, Jordi
Tahan, Nuria
Piñol Ripoll, Gerard
author_role author
author2 López Ortega, Ricard
Vilella-Figuerola, Alba
Montero-Castilla, Nathalia
Riba-Llena, Iolanda
Ruiz-Julián, Maria
Arias, Alfonso
Sarto, Jordi
Tahan, Nuria
Piñol Ripoll, Gerard
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Alzheimer’s disease
Lumipulse
Biomarker
Mild cognitive impairment
p-tau181
p-tau217
Plasma
Progression
topic Alzheimer’s disease
Lumipulse
Biomarker
Mild cognitive impairment
p-tau181
p-tau217
Plasma
Progression
description Recent studies have demonstrated the high analytical and diagnostic performance of plasma p-tau217 using well-defined cohorts. We aimed to assess the analytical, diagnostic, and prognostic utility of plasma p-tau217 as a routine biomarker in symptomatic patients attending our memory clinic. We also sought to identify optimal cutoff points that align with cerebrospinal fluid (CSF) amyloid beta (Aβ) status. A total of 276 cognitively impaired patients were included, with 81 mild cognitive impairment (MCI) patients followed for a mean of 56 (±15.8) months to evaluate progression to Alzheimer's disease (AD). CSF and blood biomarkers of AD were quantified using the Lumipulse G platform. Plasma p-tau217 levels showed strong correlations with CSF Aβ42/Aβ40 ( = -0.707), p-tau181/Aβ42 ( = 0.842), and p-tau181 (r 0.728). Plasma p-tau217 levels were significantly higher in the A + T + group than in A - T +/- ( < 0.001) and outperformed other plasma markers in detecting CSF Aβ pathology (AUC 0.924).Additionally, p-tau217 moderated cognitive changes over time as measured by the Mini-mental state examination (MMSE) (F(2, 70) = 13.995, < 0.001) and outperformed other plasma biomarkers in predicting progression from MCI to AD (AUC 0.876). Using a dual cutoff strategy, 72% of patients were classified with 94.9% concordance with CSF Aβ status. Plasma p-tau217 shows strong potential as a non-invasive, cost-effective diagnostic and prognostic tool in clinical settings.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/ijms26146771
https://hdl.handle.net/10459.1/470260
https://hdl.handle.net/10459.1/470260
url https://doi.org/10.3390/ijms26146771
https://hdl.handle.net/10459.1/470260
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ijms26146771
International Journal of Molecular Sciences, 2025, vol. 26, núm. 14
dc.rights.none.fl_str_mv cc-by (c)The Authors, 2025
Attribution 4.0 International
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c)The Authors, 2025
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411473316380672
score 15,812429

Similar Items